

# Steven G Chrysant

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2381451/publications.pdf>

Version: 2024-02-01

136  
papers

3,478  
citations

159585

30  
h-index

168389

53  
g-index

138  
all docs

138  
docs citations

138  
times ranked

3114  
citing authors

#	ARTICLE	IF	CITATIONS
1	Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. <i>Journal of Hypertension</i> , 2007, 25, 217-226.	0.5	256
2	The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. <i>Clinical Therapeutics</i> , 2008, 30, 587-604.	2.5	247
3	Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension. <i>Journal of Clinical Hypertension</i> , 2001, 3, 283-318.	2.0	233
4	Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. <i>American Journal of Hypertension</i> , 2004, 17, 252-259.	2.0	133
5	The current status of homocysteine as a risk factor for cardiovascular disease: a mini review. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 559-565.	1.5	117
6	Comparison of Amlodipine and Benazepril Monotherapy to Amlodipine Plus Benazepril In Patients with Systemic Hypertension: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 1060-1066.	2.0	82
7	Vascular remodeling: The role of angiotensin-converting enzyme inhibitors. <i>American Heart Journal</i> , 1998, 135, S21-S30.	2.7	82
8	New insights into the true nature of the obesity paradox and the lower cardiovascular risk. <i>Journal of the American Society of Hypertension</i> , 2013, 7, 85-94.	2.3	78
9	Antihypertensive Effectiveness of Low-Dose Lisinopril-Hydrochlorothiazide Combination. <i>Archives of Internal Medicine</i> , 1994, 154, 737.	3.8	64
10	Using Fixed-Dose Combination Therapies to Achieve Blood Pressure Goals. <i>Clinical Drug Investigation</i> , 2008, 28, 713-734.	2.2	61
11	Abrupt cessation of clonidine administration: A prospective study. <i>American Journal of Cardiology</i> , 1978, 41, 1285-1290.	1.6	60
12	Clinical Implications of Cardiovascular Preventing Pleiotropic Effects of Dipeptidyl Peptidase-4 Inhibitors. <i>American Journal of Cardiology</i> , 2012, 109, 1681-1685.	1.6	60
13	Efficacy and Safety of Long-Term Treatment With the Combination of Amlodipine Besylate and Olmesartan Medoxomil in Patients With Hypertension. <i>Journal of Clinical Hypertension</i> , 2009, 11, 475-482.	2.0	55
14	Antihypertensive therapy causes erectile dysfunction. <i>Current Opinion in Cardiology</i> , 2015, 30, 383-390.	1.8	55
15	Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. <i>American Journal of Cardiology</i> , 2001, 87, 727-731.	1.6	53
16	Effectiveness and Safety of Phosphodiesterase 5 Inhibitors in Patients with Cardiovascular Disease and Hypertension. <i>Current Hypertension Reports</i> , 2013, 15, 475-483.	3.5	50
17	Telmisartan/Hydrochlorothiazide in Comparison with Losartan/Hydrochlorothiazide in Managing Patients with Mild-to-Moderate Hypertension. <i>Hypertension Research</i> , 2005, 28, 555-563.	2.7	49
18	The Pleiotropic Effects of Angiotensin Receptor Blockers. <i>Journal of Clinical Hypertension</i> , 2006, 8, 261-268.	2.0	46

#	ARTICLE	IF	CITATIONS
19	Effectiveness of Lowering Blood Pressure to Prevent Stroke Versus to Prevent Coronary Events. American Journal of Cardiology, 2010, 106, 825-829.	1.6	46
20	Severe Reversible Azotemia From Captopril Therapy. Archives of Internal Medicine, 1983, 143, 437.	3.8	45
21	The single use of body mass index for the obesity paradox is misleading and should be used in conjunction with other obesity indices. Postgraduate Medicine, 2019, 131, 96-102.	2.0	45
22	Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Current Medical Research and Opinion, 2008, 24, 1039-1047.	1.9	40
23	New onset diabetes mellitus induced by statins: current evidence. Postgraduate Medicine, 2017, 129, 430-435.	2.0	37
24	Herbs Used for the Treatment of Hypertension and their Mechanism of Action. Current Hypertension Reports, 2017, 19, 77.	3.5	36
25	24-Hour Efficacy and Safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: The TRINITY Ambulatory Blood Pressure Substudy. Journal of Clinical Hypertension, 2011, 13, 873-880.	2.0	35
26	Current Evidence on the Hemodynamic and Blood Pressure Effects of Isometric Exercise in Normotensive and Hypertensive Persons. Journal of Clinical Hypertension, 2010, 12, 721-726.	2.0	33
27	Pathophysiology and treatment of obesity-related hypertension. Journal of Clinical Hypertension, 2019, 21, 555-559.	2.0	33
28	Antihypertensive Effectiveness of Amlodipine in Combination With Hydrochlorothiazide. American Journal of Hypertension, 1989, 2, 537-541.	2.0	32
29	The impact of coffee consumption on blood pressure, cardiovascular disease and diabetes mellitus. Expert Review of Cardiovascular Therapy, 2017, 15, 151-156.	1.5	32
30	The Pathophysiologic Role of the Brain Renin-Angiotensin System in Stroke Protection: Clinical Implications. Journal of Clinical Hypertension, 2007, 9, 454-459.	2.0	31
31	Proactive Compared With Passive Adverse Event Recognition: Calcium Channel Blocker-Associated Edema. Journal of Clinical Hypertension, 2008, 10, 716-722.	2.0	31
32	Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. Journal of the American Society of Hypertension, 2012, 6, 132-141.	2.3	31
33	Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. Cardiovascular Diabetology, 2012, 11, 134.	6.8	29
34	Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. Blood Pressure Monitoring, 2008, 13, 21-27.	0.8	28
35	The Pleiotropic Effects of Phosphodiesterase 5 Inhibitors on Function and Safety in Patients With Cardiovascular Disease and Hypertension. Journal of Clinical Hypertension, 2012, 14, 644-649.	2.0	28
36	Current and Future Status of Beta-blockers in the Treatment of Hypertension. Clinical Cardiology, 2008, 31, 249-252.	1.8	27

#	ARTICLE	IF	CITATIONS
37	The Treatment of Cardiovascular Disease Continuum: Focus on Pharmacologic Management and RAS Blockade. <i>Current Clinical Pharmacology</i> , 2010, 5, 89-95.	0.6	26
38	The Age-Related Hemodynamic Changes of Blood Pressure and Their Impact on the Incidence of Cardiovascular Disease and Stroke: New Evidence. <i>Journal of Clinical Hypertension</i> , 2014, 16, 87-90.	2.0	26
39	Hemodynamic and Metabolic Effects of Hypomagnesemia in Spontaneously Hypertensive Rats. <i>Cardiology</i> , 1988, 75, 81-89.	1.4	25
40	Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan®/HCT). <i>Expert Review of Cardiovascular Therapy</i> , 2003, 1, 335-343.	1.5	25
41	Results of an Olmesartan Medoxomil-Based Treatment Regimen in Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2008, 10, 911-921.	2.0	25
42	Treatment of white coat hypertension. <i>Current Hypertension Reports</i> , 2000, 2, 412-417.	3.5	24
43	Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum. <i>Clinical Therapeutics</i> , 2008, 30, 2181-2190.	2.5	24
44	Current Status of Dual Renin Angiotensin Aldosterone System Blockade for the Treatment of Cardiovascular Diseases. <i>American Journal of Cardiology</i> , 2010, 105, 849-852.	1.6	24
45	Antihypertensive and Metabolic Effects of Single and Combined Atenolol Regimens. <i>Journal of Clinical Pharmacology</i> , 1992, 32, 61-65.	2.0	23
46	Perindopril as monotherapy in hypertension: A multicenter comparison of two dosing regimens. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 53, 479-484.	4.7	23
47	Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. <i>American Journal of Hypertension</i> , 2004, 17, 590-596.	2.0	23
48	Triple-Combination Therapy with Olmesartan, Amlodipine, and Hydrochlorothiazide in Black and Non-Black Study Participants with Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 233-243.	2.2	22
49	An Update on the Cardiovascular Pleiotropic Effects of Milk and Milk Products. <i>Journal of Clinical Hypertension</i> , 2013, 15, 503-510.	2.0	22
50	Coffee Consumption and Cardiovascular Health. <i>American Journal of Cardiology</i> , 2015, 116, 818-821.	1.6	22
51	Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 657-667.	1.8	21
52	Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. <i>Blood Pressure Monitoring</i> , 2006, 11, 135-141.	0.8	21
53	Controversy Regarding the Association of High Calcium Intake and Increased Risk for Cardiovascular Disease. <i>Journal of Clinical Hypertension</i> , 2014, 16, 545-550.	2.0	20
54	Treatment of Hypertension in Patients with Atherosclerotic Renal Artery Stenosis, Updated. <i>Postgraduate Medicine</i> , 2014, 126, 59-67.	2.0	20

#	ARTICLE	IF	CITATIONS
55	Proton pump inhibitor-induced hypomagnesemia complicated with serious cardiac arrhythmias. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 345-351.	1.5	20
56	The Role of Angiotensin Receptor Blocker and Calcium Channel Blocker Combination Therapy in Treating Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 315-320.	2.2	19
57	Single-Pill Triple-Combination Therapy: An Alternative to Multiple-Drug Treatment of Hypertension. <i>Postgraduate Medicine</i> , 2011, 123, 21-31.	2.0	19
58	The Role of Angiotensin II Receptors in Stroke Protection. <i>Current Hypertension Reports</i> , 2012, 14, 202-208.	3.5	19
59	Long-term Efficacy and Safety of Triple-Combination Therapy With Olmesartan Medoxomil and Amlodipine Besylate and Hydrochlorothiazide for Hypertension. <i>Journal of Clinical Hypertension</i> , 2012, 14, 149-157.	2.0	19
60	Association of hypomagnesemia with cardiovascular diseases and hypertension. <i>International Journal of Cardiology: Hypertension</i> , 2019, 1, 100005.	2.2	19
61	Stroke prevention with losartan in the context of other antihypertensive drugs. <i>Drugs of Today</i> , 2004, 40, 791.	2.4	18
62	Effects of High Salt Intake on Blood Pressure and Cardiovascular Disease: The Role of COX Inhibitors. <i>Clinical Cardiology</i> , 2016, 39, 240-242.	1.8	17
63	Aggressive systolic blood pressure control in older subjects: benefits and risks. <i>Postgraduate Medicine</i> , 2018, 130, 159-165.	2.0	17
64	Long-term efficacy, safety, and tolerability of valsartan and hydrochlorothiazide in patients with essential hypertension. <i>Current Therapeutic Research</i> , 1998, 59, 762-772.	1.2	16
65	Antihypertensive Effectiveness of a Very Low Fixed-Dose Combination of Moexipril and Hydrochlorothiazide. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 31, 384-390.	1.9	16
66	Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension. <i>Current Medical Research and Opinion</i> , 2010, 26, 2841-2849.	1.9	15
67	Current Status of Aggressive Blood Glucose and Blood Pressure Control in Diabetic Hypertensive Subjects. <i>American Journal of Cardiology</i> , 2011, 107, 1856-1861.	1.6	15
68	Treatment of hypertension in patients with renal artery stenosis due to fibromuscular dysplasia of the renal arteries. <i>Cardiovascular Diagnosis and Therapy</i> , 2014, 4, 36-43.	1.7	15
69	Antihypertensive effects of mibefradil: A double-blind comparison with diltiazem CD. <i>Clinical Cardiology</i> , 1997, 20, 562-568.	1.8	14
70	Clinical Experience With Angiotensin Receptor Blockers With Particular Reference to Valsartan. <i>Journal of Clinical Hypertension</i> , 2004, 6, 445-451.	2.0	14
71	The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. <i>Blood Pressure</i> , 2007, 16, 10-17.	1.5	14
72	Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan. <i>Journal of the American Society of Hypertension</i> , 2017, 11, 461-468.	2.3	14

#	ARTICLE	IF	CITATIONS
73	Perindopril/Hydrochlorothiazide Dose Combinations for the Treatment of Hypertension: A Multicenter Study. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 47-52.	2.0	13
74	Future of Polypill Use for the Prevention of Cardiovascular Disease and Strokes. <i>American Journal of Cardiology</i> , 2014, 114, 641-645.	1.6	13
75	The current debate over treatment of subclinical hypothyroidism to prevent cardiovascular complications. <i>International Journal of Clinical Practice</i> , 2020, 74, e13499.	1.7	12
76	Stopping the cardiovascular disease continuum: Focus on prevention. <i>World Journal of Cardiology</i> , 2010, 2, 43.	1.5	12
77	Hemodynamic Effects of Isometric Exercise in Normotensive Hypertensive Subjects Hypertension. <i>Angiology</i> , 1978, 29, 379-385.	1.8	11
78	Aliskirenâ€“hydrochlorothiazide combination for the treatment of hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 305-314.	1.5	11
79	The clinical significance of isolated diastolic hypertension. <i>Postgraduate Medicine</i> , 2020, 132, 624-628.	2.0	11
80	Effects of Amiloride on Arterial Pressure and Renal Function. <i>Journal of Clinical Pharmacology</i> , 1980, 20, 332-337.	2.0	10
81	Treatment of Severe Hypertension with Atenolol and Betaxolol with Once-Daily Regimens. <i>Chest</i> , 1989, 96, 499-504.	0.8	10
82	Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension. <i>Journal of Clinical Hypertension</i> , 2018, 20, 351-355.	2.0	10
83	Clinical Utility of Longâ€“Term Enalapril/Diltiazem ER in Stage 3â€“4 Essential Hypertension. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 810-815.	2.0	9
84	Pharmacological and Clinical Profile of Moexipril: A Concise Review. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 827-836.	2.0	9
85	Niacin-ER/Statin Combination for the Treatment of Dyslipidemia: Focus on Low High-Density Lipoprotein Cholesterol. <i>Journal of Clinical Hypertension</i> , 2006, 8, 493-501.	2.0	9
86	Irbesartan/Hydrochlorothiazide for the Treatment of Isolated Systolic Hypertension:A Subgroup Analysis of the INCLUSIVE Trial. <i>Journal of the National Medical Association</i> , 2009, 101, 300-307.	0.8	8
87	Usefulness of the Polypill for the Prevention of Cardiovascular Disease and Hypertension. <i>Current Hypertension Reports</i> , 2016, 18, 14.	3.5	8
88	New evidence for the diastolic Jâ€“curve effect challenges theâ€“safety of intensive blood pressure control. <i>Journal of Clinical Hypertension</i> , 2017, 19, 340-343.	2.0	8
89	Renal Functional and Organic Changes Induced by Salt and Prostaglandin Inhibition in Spontaneously Hypertensive Rats. <i>Nephron</i> , 1980, 25, 151-155.	1.8	7
90	Sustained Blood Pressure Control with Controlledâ€“Release Isradipine (Isradipineâ€“CR). <i>Journal of Clinical Pharmacology</i> , 1995, 35, 239-243.	2.0	7

#	ARTICLE	IF	CITATIONS
91	Clinical Experience with the Use of Angiotensin Receptor Blockers in Patients with Cardiovascular, Cerebrovascular and Renal Diseases. <i>Current Clinical Pharmacology</i> , 2006, 1, 139-146.	0.6	7
92	Combination Therapy with Olmesartan Medoxomil and Hydrochlorothiazide. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 241-251.	2.2	7
93	Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1115-1124.	1.5	7
94	The Current Status of Angioplasty of Atherosclerotic Renal Artery Stenosis for the Treatment of Hypertension. <i>Journal of Clinical Hypertension</i> , 2013, 15, 694-698.	2.0	7
95	Cardiovascular benefits and risks of testosterone replacement therapy in older men with low testosterone. <i>Hospital Practice (1995)</i> , 2018, 46, 47-55.	1.0	7
96	Obesity-related heart failure with preserved ejection fraction: new treatment strategies. <i>Hospital Practice (1995)</i> , 2019, 47, 67-72.	1.0	7
97	The tilt table test is useful for the diagnosis of vasovagal syncope and should not be abolished. <i>Journal of Clinical Hypertension</i> , 2020, 22, 686-689.	2.0	7
98	The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan. <i>Drugs of Today</i> , 2010, 46, 151.	1.1	7
99	Effects of atenolol and diltiazem on exercise and pressure load in hypertensive patients. <i>Clinical Cardiology</i> , 1994, 17, 670-674.	1.8	6
100	Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 887-895.	1.5	6
101	The Cardiovascular Consequences of Excess Sitting Time. <i>Journal of Clinical Hypertension</i> , 2015, 17, 528-531.	2.0	6
102	Association of Exposure to Bisphenol A and Incidence of Cardiovascular Disease and Hypertension. <i>Journal of Clinical Hypertension</i> , 2015, 17, 737-739.	2.0	6
103	Adverse cardiovascular and blood pressure effects of drug-induced hypomagnesemia. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 59-67.	2.4	6
104	Treating blood pressure to prevent strokes: The age factor. <i>World Journal of Cardiology</i> , 2013, 5, 22.	1.5	6
105	Review of the Safety and Efficacy of Linagliptin as Add-On Therapy to Metformin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study. <i>Postgraduate Medicine</i> , 2011, 123, 183-186.	2.0	5
106	A Healthy Lifestyle Could Reduce the Onset of First Heart Attack by 80%. <i>Journal of Clinical Hypertension</i> , 2015, 17, 168-171.	2.0	5
107	Dual Renin-Angiotensin-Aldosterone Blockade: Promises and Pitfalls. <i>Current Hypertension Reports</i> , 2015, 17, 511.	3.5	5
108	The Clinical Significance of N-terminal Pro-Brain Natriuretic Peptide in Detecting the Residual Cardiovascular Risk in Hypertension and Other Clinical Conditions and in Predicting Future Cardiovascular Events. <i>Journal of Clinical Hypertension</i> , 2016, 18, 718-720.	2.0	5

#	ARTICLE	IF	CITATIONS
109	Obesity is bad regardless of the obesity paradox for hypertension and heart disease. <i>Journal of Clinical Hypertension</i> , 2018, 20, 842-846.	2.0	5
110	Sacubitril/valsartan: a cardiovascular drug with pluripotential actions. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 543-548.	1.7	5
111	New and emerging cardiovascular and antihypertensive drugs. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1315-1327.	2.4	5
112	Noninvasive vascular function tests for the future prediction of primary cardiovascular diseases. <i>Hospital Practice (1995)</i> , 2020, 48, 113-118.	1.0	5
113	Antihypertensive and cardioprotective effects of three generations of beta-adrenergic blockers: an historical perspective. <i>Hospital Practice (1995)</i> , 2022, 50, 196-202.	1.0	5
114	Safety and Tolerability of an Olmesartan Medoxomil-Based Regimen in Patients with Stage 1 Hypertension. <i>Clinical Drug Investigation</i> , 2010, 30, 473-482.	2.2	4
115	Olmesartan Medoxomil-Based Antihypertensive Therapy Evaluated by Ambulatory Blood Pressure Monitoring. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 375-389.	2.2	4
116	A novel approach for the treatment of hypertension with the soluble guanylate cyclase stimulating drug. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 635-640.	2.4	4
117	The Debate Over Egg Consumption and Incident Cardiovascular Disease. <i>Cardiology in Review</i> , 2021, 29, 238-244.	1.4	4
118	Beneficial cardiovascular and remodeling effects of SGLT 2 inhibitors. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 223-232.	1.5	4
119	Amlodipine/ARB fixed-dose combinations for the treatment of hypertension: Focus on amlodipine/olmesartan combination. <i>Drugs of Today</i> , 2008, 44, 443.	1.1	4
120	Pharmacological profile and clinical use of moexipril. <i>Expert Review of Cardiovascular Therapy</i> , 2003, 1, 345-352.	1.5	3
121	Treatment of Modifiable Risk Factors Is Associated With Decrease in Coronary Heart Disease Incidence: Time to Use the Polypill. <i>Journal of Clinical Hypertension</i> , 2016, 18, 840-842.	2.0	3
122	The cardiometabolic benefits of exercise in postmenopausal women. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1691-1693.	2.0	3
123	Achieving blood pressure targets for prolonged cardiovascular health: a historical perspective. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 517-523.	1.5	3
124	Reliability of Blood Pressure Monitoring With Wearable Cuffless Devices. <i>American Journal of Cardiology</i> , 2022, , .	1.6	3
125	Effects of Diet on Exaggerated Natriuresis in Hypertension. <i>Clinical and Experimental Hypertension</i> , 1981, 3, 55-68.	1.3	2
126	Has the role of calcium channel blockers in treating hypertension finally been defined?. <i>Current Hypertension Reports</i> , 2003, 5, 295-300.	3.5	2



#	ARTICLE	IF	CITATIONS
127	Authors reply: statins and new onset of diabetes: which one outweighs risk or benefit?. Postgraduate Medicine, 2018, 130, 147-147.	2.0	1
128	In response to: an opposing point of view on the obesity paradox. Postgraduate Medicine, 2019, 131, 388-389.	2.0	1
129	Orthostatic hypotension and cardiovascular outcomes: Should we be concerned?. Journal of Clinical Hypertension, 2020, 22, 2161-2162.	2.0	1
130	The debate over the optimal blood pressure treatment target of less than 130/80 mmHg. Postgraduate Medicine, 2023, 135, 208-213.	2.0	1
131	Combination therapy with an ace-inhibitor (acei)/calcium channel blocker (ccb) for hypertensive patients non-responsive to ace-inhibitor monotherapy: an efficacy and safety trial. American Journal of Hypertension, 2004, 17, S102.	2.0	0
132	Olmesartan medoxomil lowers blood pressure as rapidly as amlodipine besylate in patients with mild to moderate hypertension: results of a randomized, double-blind, placebo-controlled study. American Journal of Hypertension, 2004, 17, S102.	2.0	0
133	Blood Pressure Effects of High-Dose Amlodipine-Benazepril Combination in Black and White Hypertensive Patients Not Controlled on Monotherapy. Drugs in R and D, 2012, 12, 57-64.	2.2	0
134	New noninvasive vascular tests could improve the prediction and early diagnosis and treatment of cardiovascular diseases. Journal of Clinical Hypertension, 2019, 21, 893-895.	2.0	0
135	The pathophysiology and management of diuretic resistance in patients with heart failure. Hospital Practice (1995), 2021, , 1-9.	1.0	0
136	Early and sustained blood pressure control is necessary for stroke prevention. Journal of Thoracic Disease, 2015, 7, 1070-3.	1.4	0